Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit?

Authors Saltürk C, Karakurt Z, Adiguzel N, Kargin F, Sari R, Celik ME, Takir HB, Tuncay E, Sogukpinar O, Ciftaslan N, Mocin O, Gungor G, Oztas S

Received 6 May 2015

Accepted for publication 24 July 2015

Published 8 September 2015 Volume 2015:10(1) Pages 1837—1846

DOI https://doi.org/10.2147/COPD.S88058

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Hsiao-Chi Chuang

Peer reviewer comments 5

Editor who approved publication: Dr Richard Russell

Cüneyt Saltürk, Zuhal Karakurt, Nalan Adiguzel, Feyza Kargin, Rabia Sari, M Emin Celik, Huriye Berk Takir, Eylem Tuncay, Ozlem Sogukpinar, Nezihe Ciftaslan, Ozlem Mocin, Gokay Gungor, Selahattin Oztas

Respiratory Intensive Care Unit, Sureyyapasa Chest Diseases and Thoracic Surgery Teaching Hospital, Istanbul, Turkey

Background: COPD exacerbations requiring intensive care unit (ICU) admission have a major impact on morbidity and mortality. Only 10%–25% of COPD exacerbations are eosinophilic.
Aim: To assess whether eosinophilic COPD exacerbations have better outcomes than non-eosinophilic COPD exacerbations in the ICU.
Methods: This retrospective observational cohort study was conducted in a thoracic, surgery-level III respiratory ICU of a tertiary teaching hospital for chest diseases from 2013 to 2014. Subjects previously diagnosed with COPD and who were admitted to the ICU with acute respiratory failure were included. Data were collected electronically from the hospital database. Subjects’ characteristics, complete blood count parameters, neutrophil to lymphocyte ratio (NLR), delta NLR (admission minus discharge), C-reactive protein (CRP) on admission to and discharge from ICU, length of ICU stay, and mortality were recorded. COPD subjects were grouped according to eosinophil levels (>2% or ≤2%) (group 1, eosinophilic; group 2, non-eosinophilic). These groups were compared with the recorded data.
Results: Over the study period, 647 eligible COPD subjects were enrolled (62 [40.3% female] in group 1 and 585 [33.5% female] in group 2). Group 2 had significantly higher C-reactive protein, neutrophils, NLR, delta NLR, and hemoglobin, but a lower lymphocyte, monocyte, and platelet count than group 1, on admission to and discharge from the ICU. Median (interquartile range) length of ICU stay and mortality in the ICU in groups 1 and 2 were 4 days (2–7 days) vs 6 days (3–9 days) (P<0.002), and 12.9% vs 24.9% (P<0.034), respectively.
Conclusion: COPD exacerbations with acute respiratory failure requiring ICU admission had a better outcome with a peripheral eosinophil level >2%. NLR and peripheral eosinophilia may be helpful indicators for steroid and antibiotic management.

Keywords: chronic obstructive pulmonary disease, exacerbation, respiratory failure, intensive care unit, peripheral eosinophilia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Comparison of exercise capacity in COPD and other etiologies of chronic respiratory failure requiring non-invasive mechanical ventilation at home: retrospective analysis of 1-year follow-up

Salturk C, Karakurt Z, Takir HB, Balci M, Kargin F, Mocin OY, Gungor G, Ozmen I, Oztas S, Yalcinsoy M, Evin R, Ozturk M, Adiguzel N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2559-2569

Published Date: 26 November 2015

Readers of this article also read:

Molecular targets in arthritis and recent trends in nanotherapy

Roy K, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:5407-5420

Published Date: 26 August 2015

Public attitudes about lung cancer: stigma, support, and predictors of support

Weiss J, Stephenson BJ, Edwards LJ, Rigney M, Copeland A

Journal of Multidisciplinary Healthcare 2014, 7:293-300

Published Date: 16 July 2014

Complex role of HIF in cancer: the known, the unknown, and the unexpected

Tiburcio PD, Choi H, Huang LE

Hypoxia 2014, 2:59-70

Published Date: 18 June 2014

The potential clinical applications and prospects of microRNAs in lung cancer

Gao Y, Gao F, Ma JL, Sun WZ, Song LP

OncoTargets and Therapy 2014, 7:901-906

Published Date: 4 June 2014

Ulcerative colitis six years after colon cancer: only a coincidence?

Sakellakis M, Makatsoris T, Gkermpesi M, Peroukidis S, Kalofonos H

International Medical Case Reports Journal 2014, 7:85-88

Published Date: 29 April 2014

Breast cancer causes and treatment: where are we going wrong?

Seymour CB, Mothersill C

Breast Cancer: Targets and Therapy 2013, 5:111-119

Published Date: 3 December 2013

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010